Advocates push for integration of HIV/TB funding, programming in Kenya

NewsGuard 100/100 Score

This post in the Center for Global Health Policy's "Science Speaks" blog reports on a presentation at the Union World Conference on Lung Health in France on Saturday by Evelyne Kibuchi, a senior tuberculosis (TB) advocacy officer at the Kenya AIDS NGOs Consortium (KANCO), writing, "HIV stakeholders have been slow to embrace and adopt TB interventions, Kibuchi said, and resources for co-infection activities are modest. Other challenges include the low profile of TB in Kenya despite its high disease burden and the slow flow of funding, especially from the Global Fund to Fight AIDS, Tuberculosis and Malaria. KANCO supports TB/HIV integration by working to educate and sensitize both HIV and TB stakeholders to the issues related to TB/HIV co-infection" (Lubinski, 10/31).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    New drug candidates show promise to reverse HIV immune evasion